Covered recipient · General Payments record
YUSEF WILLIAMS
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$3,229.74
- Reported across 189 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $691.42 | 35 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $222.50 | 16 |
| Novo Nordisk AS | $215.24 | 6 |
| Acerta Pharma LLC | $91.79 | 4 |
| PFIZER INC. | $90.95 | 5 |
| Nevro Corp. | $22.38 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $19.30 | 1 |
| GlaxoSmithKline, LLC. | $15.47 | 1 |
| Lilly USA, LLC | $13.79 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (35)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $17.49 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106342900 | CMS |
| ABBVIE INC. | $8.50 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106342902 | CMS |
| ABBVIE INC. | $24.05 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106342904 | CMS |
| ABBVIE INC. | $18.35 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106342906 | CMS |
| ABBVIE INC. | $11.56 | 04/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106342908 | CMS |
| ABBVIE INC. | $10.63 | 04/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106342910 | CMS |
| ABBVIE INC. | $4.04 | 05/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106342912 | CMS |
| ABBVIE INC. | $16.10 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106342914 | CMS |
| ABBVIE INC. | $9.82 | 06/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106342916 | CMS |
| ABBVIE INC. | $9.71 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106342918 | CMS |
| ABBVIE INC. | $24.52 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106342920 | CMS |
| ABBVIE INC. | $12.54 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106342922 | CMS |
| ABBVIE INC. | $19.89 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106342924 | CMS |
| ABBVIE INC. | $18.24 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106342926 | CMS |
| ABBVIE INC. | $5.60 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106342928 | CMS |
| ABBVIE INC. | $11.46 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106342930 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.36 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105809671 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.73 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104205541 | CMS |
| AstraZeneca Pharmaceuticals LP | $33.45 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105532592 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.25 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105769112 | CMS |
| GlaxoSmithKline, LLC. | $15.47 | 03/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116468198 | CMS |
| Lilly USA, LLC | $13.79 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135511371 | CMS |
| Nevro Corp. | $22.38 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130744199 | CMS |
| Novartis Pharmaceuticals Corporation | $19.30 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087408568 | CMS |
| Novo Nordisk Inc | $18.62 | 01/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096828602 | CMS |
| Novo Nordisk Inc | $24.09 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096580413 | CMS |
| Novo Nordisk Inc | $24.09 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096982027 | CMS |
| Novo Nordisk Inc | $114.49 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096969292 | CMS |
| Novo Nordisk Inc | $16.94 | 06/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097414495 | CMS |
| Novo Nordisk Inc | $17.01 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096929992 | CMS |
| PFIZER INC. | $17.76 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131187464 | CMS |
| PFIZER INC. | $16.47 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131144764 | CMS |
| PFIZER INC. | $18.80 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131687984 | CMS |
| PFIZER INC. | $19.89 | 06/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131526424 | CMS |
| PFIZER INC. | $18.03 | 08/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131781426 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.